Nektar Therapeutics (NKTR) Posts Q2 EPS Loss of $0.32, Revenues 60% Y/Y
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $65.70 --0%
Revenue Growth %: -7.1%
Financial Fact:
Net loss: -43.22M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: -7.1%
Financial Fact:
Net loss: -43.22M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.32), $0.01 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $17.3 million versus the consensus estimate of $14.89 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary
- Jabil beats consensus estimates but shares dip
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
